Elan Seeks Arbitration With Pfizer Over Alzheimer Research
The dispute concerns a research, development and marketing agreement, originally entered into with Pharmacia in August 2000. The research centered on the discovery of small molecule inhibitors of beta secretase at the research stage for the treatment of Alzheimer's disease, according to Elan.
The Irish drug maker said it had taken the step following the termination of an agreement with Pfizer to jointly...
To view the full article, register now.